BetterLife Pharma Inc. announced it has completed its 4-week oral BETR-001 GLP toxicology study in animals. The study demonstrated that BETR-001's repeated dosing for 4 weeks is very well-tolerated. The study findings support a broad therapeutic window for the use of BETR-001 in humans.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0753 USD | -1.62% | +1.07% | +56.88% |
Apr. 03 | BetterLife Pharma Inc. announced that it has received CAD 1.168 million in funding | CI |
Mar. 04 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+56.88% | 8.88M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001